Always a pleasure to catch-up with Editorial Board member, Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden), who chatted with us on several topics including the MOPEAD initiative. MOPEAD (Models of Patient Engagement for Alzheimer’s disease), aims to deliver a step-change in AD patient engagement strategies and a paradigm shift from late-stage diagnosis to early-stage diagnosis. It strives to improve the identification of subjects with mild cognitive impairment at an early stage. For more information visit: https://www.mopead.eu/
1. Could you give us a brief overview of the aims and design of the Models Of Patient Engagement for Alzheimer’s Disease (MOPEAD) project? (0:05)
2. What have been the major findings of the project to date? (4:03)
Also see linked videos with Bengt Winblad:
Emerging therapeutic targets for Alzheimer’s disease
Targeting Beta-amyloid for the Treatment of Early Alzheimer’s
Swedish Geriatric Neurologist Perspective on COVID-19
Speaker disclosure: Bengt Winblad has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Michael Weiner, AD/PD 2021: The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
It was a great pleasure to meet with Michael Weiner (University of California, San Francisco, CA, USA), the Principal Investigator for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), to discuss the initiative’s aims, design and future developments. The abstract entitled ‘Validating Plasma Tests for Amyloid, Tau, and Neurodegeneration Using the Alzheimer’s Disease Neuroimaging Initiative (ADNI)’ was […]
Marwan Sabbagh, AD/PD 2021: Phase 2 MCLENA-1 Trial
TouchNEUROLOGY had the great pleasure of speaking with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA) to discuss the phase 2 MCLENA-1 clinical trial rationale, assessing lenalidomide in patients with mild cognitive impairment due to Alzheimer’s Disease. The abstract entitled ‘Rationale for the MCLENA-1: A Phase II Clinical Trial for the Assessment […]
Yona Levites, AD/PD 2021: Immunotherapeutic Approaches in Alzheimer’s Disease (Part 1)
We had the pleasure of meeting with Yona Levites (Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA) to discuss immunotherapeutic approaches in Alzheimer’s Disease. Part 2 of the discussion can be viewed here. The abstract entitled ‘Immunotherapeutic approaches in Alzheimer’s Disease’ was presented at The 15th International Conference for Alzheimer’s […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!